La Jolla, California
Xeomin is the newest “frown fixer” available to patients across the country. Pronounced zee-oh-min, the new tox product acts like its predecessors Botox and Dysport in reducing or preventing contractions of the glabellar muscle between the eyes.
How is Xeomin different from Botox or Dysport?
The difference in Xeomin (incobotulinumtoxinA) is that it does not carry the proteins that are typical of the other products. The potential advantage lies in the lessened likelihood of antibodies being formed to the proteins which – for a very limited number of patients – can render the product ineffective. (This typically is only seen in patients who have used botulinum toxin for an extended period of time.)
How is Xeomin similar to Botox or Dysport?
The muscle-restricting action is, for all practical purposes, like Botox and Dysport and the dosing will be the same as Botox. So if you’re accustomed to 20 units of Botox, expect to receive 20 units of Xeomin for the same effect and area.
Why would I choose Xeomin over the injectables already available for a longer period of time?
At the introduction of Xeomin, the manufacturer priced the product a bit lower, so price could be one reason. It’s slightly quicker effect could be another. We frequently use both Dysport and Botox in a single session to achieve desired results. We do the same with Xeomin. Which to choose is doctor/ patient preference and injection location. We just want you to look good.
How fast does Xeomin work?
Xeomin takes effect within 2-3 days after injection with effectiveness ranging up to 4 months.
FDA Approval of Xeomin
The FDA approval of XEOMIN is based on the results of two pivotal U.S. clinical trials involving 16 investigational sites and included 547 healthy adult patients. In both studies, XEOMIN significantly improved the appearance of glabellar lines 30 days following the first injection, when compared to placebo. XEOMIN is the only botulinum toxin currently approved in the U.S. that does not require refrigeration prior to reconstitution.
“XEOMIN is a promising new option for both patients and physicians and we are encouraged by the response rates seen in the Phase III clinical trials,” said Derek H. Jones, M.D., an investigator for the XEOMIN U.S. study, Clinical Associate Professor of Medicine at the University of California in Los Angeles, Calif., and Director of Skin Care and Laser Physicians in Beverly Hills, Calif.
Xeomin is used in 14 worldwide locations and in the EU under the name Bocouture. As with all botulinum toxins, there are safety warnings that must be made public.